LAUSR

This Phase 3 randomized, double-blind study in adults with T2DM (A1C 7.0-10.5%) on MET monotherapy (≥1500 mg/day ≥8 weeks) included a 26 week placebo (PBO)-controlled period followed by a 78 week extension where non-rescued PBO pts with fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride (GLIM). Efficacy, safety and effect on bone mineral density (BMD) of ertugliflozin (ERTU) 5 mg and 15 mg QD at week 104 are reported. Pts (N=621) had baseline mean ± SD: age 56.6 ± 8.8 y; T2DM duration 8.0 ± 6.0 y; BMI 31.1 ± 4.7 kg/m2; A1C 8.1 ± 0.9%. 41% were post-menopausal women. At week 104, ERTU 5 mg and ERTU 15 mg reduced A1C, FPG, body weight (BW) and blood pressure (BP) compared to baseline, and increased the proportion of pts with A1C Incidence of female genital mycotic infections was higher in ERTU 5 mg (7.3%; p=0.017) and 15 mg (9.8%; p=0.003) vs. PBO/GLIM (0.9%). Symptomatic hypoglycemia was lower in ERTU 5 mg (5.8%; p=0.009) and 15 mg (5.9%; p=0.009) vs. PBO/GLIM (13.4%). ERTU had no impact on BMD vs. PBO/GLIM, except total hip where BMD reduction was greater for ERTU 15 mg (Table). Fractures occurred in 3, 2 and 7 pts in ERTU 5 mg, 15 mg and PBO/GLIM, respectively. ERTU added to MET in pts with inadequately controlled T2DM improved glycemic control, BW and BP over 104 weeks. ERTU was well tolerated with no clinically meaningful impact on BMD. Disclosure S. Gallo: Employee; Self; Pfizer Inc. B. Charbonnel: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Sanofi, Takeda Development Centre Europe Ltd. A. Goldman: Stock/Shareholder; Self; Merck & Co., Inc.. Employee; Self; Pfizer Inc.. Stock/Shareholder; Self; Pfizer Inc. H. Shi: Employee; Self; Pfizer Inc. S. Huyck: Employee; Self; Merck & Co., Inc. A. Darekar: Employee; Self; Pfizer Inc.. Stock/Shareholder; Self; Pfizer Inc. B. Lauring: Employee; Self; Merck & Co., Inc. S. Terra: Employee; Self; Pfizer Inc..